The aim of the study was the assessment of the impact of supplementation with folic acid on the concentration of homocysteine, total cholesterol (TC), HDL-and LDLcholesterol, triglycerides (TG), apoprotein AI (apoAI) and apoprotein B (apoB) in patients suffering from primary hypertension. The examined group comprised 42 patients suffering from primary hypertension. All examined patients underwent laboratory tests as follows: concentration of homocysteine, folic acid, TC, LDL-cholesterol, HDL-cholesterol, TG, apoAI and apoB. All patients were orally administered with 15 mg of folic acid per day for 45 d. After this period, all laboratory tests were repeated. Homocysteine concentration was measured by the FPIA method, concentrations of apoAI and apoB were measured by the nephelometric method, and other parameters with routine methods. After administration of 15 mg of folic acid to patients with primary hypertension, a considerable decrease in the concentration of homocysteine was observed in parallel with a substantive growth of HDLcholesterol, as well as apoprotein AI concentrations and a reduction of the apoprotein B concentration. Results of statistical analysis indicated a significant correlation between the decline in homocysteine concentration and the increase in HDL-cholesterol concentration, as well as between the increase of folic acid concentration and the increase in apoAI concentration in patients following the intake of folic acid. The drop in homocysteine concentration through the supplementation with folic acid can cause quantitative changes in the lipid and lipoprotein parameters which, in consequence, may lead to the mitigation of risk concerning the development of atherosclerosis. Key Words hypertension, hyperhomocysteinaemia, cholesterol, triglycerides, apoproteins Hypertension is one of the most common symptoms of cardiovascular diseases. Ninety percent of affected patients are diagnosed with primary hypertension. The etiology of this disease includes numerous genetic, environmental and neuro-hormonal factors, which often co-exist and are linked one to another. Due to that fact, hypertension is frequently accompanied by metabolic disorders such as obesity, diabetes, and hyperlipidaemia. These diseases are often also accompanied by mild chronic inflammation, disorders of the coagulation system and fibrinolysis, as well as hyperhomocysteinaemia. Some of the cardiovascular disease risk factors may be modified through a change in lifestyle and medication. The positive impact of modified standard risk factors, such as disturbances in lipid and carbohydrate metabolism disorders, as well as obesity, is relatively well documented.
Hypertension is one of the most common symptoms of cardiovascular diseases. Ninety percent of affected patients are diagnosed with primary hypertension. The etiology of this disease includes numerous genetic, environmental and neuro-hormonal factors, which often co-exist and are linked one to another. Due to that fact, hypertension is frequently accompanied by metabolic disorders such as obesity, diabetes, and hyperlipidaemia. These diseases are often also accompanied by mild chronic inflammation, disorders of the coagulation system and fibrinolysis, as well as hyperhomocysteinaemia. Some of the cardiovascular disease risk factors may be modified through a change in lifestyle and medication. The positive impact of modified standard risk factors, such as disturbances in lipid and carbohydrate metabolism disorders, as well as obesity, is relatively well documented.
As far as hyperhomocysteinaemia is concerned, studies on its importance in the development of hypertension, as well as on the impact of its treatment in eliminating the risk of cardiovascular diseases, are still being carried out. High blood pressure is often accompanied by hyperhomocysteinaemia. High level of homocysteine could adversely affect the synthesis and bioaccessibility of nitrogen oxide, which is a strong endothelial vasodilator. Apart from that, hyperhomocysteinaemia affects blood vessel wall remodeling and accelerates vessels fibrosis and calcification. In addition, a positive correlation between concentration of homocysteine in blood serum and lipoproteins disorders has been observed. In summary, hyperhomocysteinaemia might contribute to the development and consolidation of hypertension (1) . However, a decrease of the level of homocysteine is possible through the administration of folic acid (2) .
The aim of the study was to assess the impact of supplementation with folic acid on the concentration of homocysteine, total cholesterol (TC), HDL-and LDLcholesterol, triglycerides (TG), apoprotein AI (apoAI) and apoprotein B (apoB) in patients suffering from primary hypertension.
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MATERIALS AND METHODS
Clinical examination was approved by the Bioethical Commission of the Poznań University of Medical Sciences (Resolution No. 777/06). The examination was carried out in 42 patients suffering from primary hypertension, including 21 women and 21 men, aged 22-57 y, undergoing treatment at the Department and Clinic of Internal Medicine, Metabolic Disorders and Hypertension, at the University of Medical Sciences in Poznań, Poland. Primary active hypertension was documented based on at least 18 mo of medical records. The examined patients did not suffer from any other cardiovascular disease (coronary heart disease, cerebral stroke, or peripheral vascular disease) or hypertensive complications. Patients suspected of suffering from kidney diseases, psoriasis, neoplastic diseases, hormonal disturbances, hepatocellular damage, diabetes and neurological diseases were excluded from the study. Patients who had undergone surgery in the past 6 mo and/ or had suffered from inflammatory diseases in the last 3 mo, as well as pregnant women, were also ruled out of the study.
Once the patients were approved to participate in the research programme, their written consent was obtained. Twelve-hour fasting blood samples were obtained from a vein while participants were in a siting posture. Five milliliters of venous blood was taken with the use of the S-Monovette ® -blood collection system (Sarstedt), after which it was centrifuged at 350 3g for 10 min. The serum was transferred to a 5 mL tube. The following laboratory tests were conducted: measurements of homocysteine, folic acid, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides (TG), as well as levels of apoprotein AI and apoprotein B.
The group of patients with primary hypertension was divided into 2 groups: patients with normohomocysteinaemia and patients with hyperhomocysteinaemia. Patients with a homocysteine concentration of #12 mmol/L were classified into the group of patients with normohomocysteinaemia, while patients with homocysteine concentration .12 mmol/L were classified into the group of patients with hyperhomocysteinaemia. Cut-off points were adopted in accordance with the recommendation of the manufacturer of the test for determination of homocysteine level by microparticle enzyme immunoassay.
All patients suffering from primary hypertension were given 15 mg folic acid orally, once a day, for 45 d. During that time, the patients continued hypertensive treatment, but were not given either statins or any other medicines reducing the concentration of cholesterol and/or triglycerides. After 45 d of folic acid supplementation, the same parameters were measured. Laboratory tests were carried out in the Department of Laboratory Diagnostics at Poznań University of Medical Sciences. The concentration of homocysteine in serum was measured by the fluorescence polarization immunoassay (FPIA) method, while the concentration of folic acid in serum was measured by the microparticle enzyme immunoassay (MEIA) method with use of the AxSYM analyser (Abbott). The lipid parameters (total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides) were measured by standard methods with use of the Dimension biochemical analyser (Siemens). The level of apoAI and apoB was measured by the immunonephelometry method with use of the BNII analyser (Siemens).
Statistical analysis. The results concerning homocysteine, folic acid, total cholesterol, HDL-cholesterol, LDLcholesterol, triglycerides, apoprotein AI and apoprotein B were statistically analysed. In order to examine the distribution of concentrations of examined parameters the Shapiro-Wilk test was applied. Some parameters showed a compliance with normal distribution; others did not. Therefore, in the tables the arithmetic mean, standard deviation, and median are given.
For comparison of the results obtained before and after the supplementation with folic acid, the Wilcoxon signed-rank test was applied in order to assess the dependent variables. In order to determine the correlation between the concentration of homocysteine and the concentration of total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, apoprotein AI and apoprotein B, the Spearman correlation coefficients were applied. All statistical hypotheses were accepted at the 
RESULTS
The selected parameters of the clinical characteristics of the examined group of patients suffering from primary hypertension are presented in Table 1 . After the administration of 15 mg of folic acid once a day for 45 d, further medical examination in patients was performed and concentrations of all previously studied biochemical parameters were measured. The measurement of arterial pressure showed that both systolic and diastolic pressure fell. A significant lowering of systolic pressure (from 153.14 to 143.33 mmHg) and also of n: number of people in the study group, [%]: average increase or decrease in biochemical parameter concentration after supplementation with folic acid, as a percentage, N↑: number of patients in whom the serum biochemical parameter concentrations increased after administration of folic acid, N0: number of patients whose serum biochemical parameter levels did not change after the administration of folic acid, N↓: number of patients whose serum biochemical parameter levels decreased after administration of folic acid. * Statistically significant difference compared to the concentration in serum before the administration of folic acid, at the significance level of p,0.05. n: number of people in the study group, [%]: average increase or decrease biochemical parameter concentration after supplementation with folic acid, as a percentage, N↑: number of patients in whom the serum biochemical parameter concentration increased after administration of folic acid, N0: number of patients with serum biochemical parameter levels which did not change after the administration of folic acid, N↓: number of patients whose serum biochemical parameter levels decreased after the administration of folic acid. * Statistically significant difference compared to biochemical parameter concentration in serum before the administration of folic acid, at the significance level of p,0.05. average diastolic pressure (from 97 to approximately 90 mmHg) was observed.
In the patients suffering from hypertension, changes in the concentration of homocysteine as well as lipid and lipoprotein parameters in serum were observed (Table 2) . Along with the increase in the folic acid concentration, the homocysteine concentration in serum decreased in 89% of patients suffering from normohomocysteinaemia and in 100% of patients with hyperhomocysteinaemia (Table 3) . After the folic acid administration, the number of patients with hyperhomocysteinaemia (Hcy .12 mmol/L) was 5 times lower compared to the pre-supplementation condition. Post supplementation of patients with folic acid, the average concentration of total cholesterol and LDL-cholesterol decreased, in particular in patients with primary hypertension and hyperhomocysteinaemia. These changes, however, were not statistically significant (Table 3) . On the other hand, a significant increase in HDL-cholesterol in the serum of patients with primary hypertension was observed ( Table 2 ). The average increase in HDL-cholesterol concentration was considerably higher in patients with hyperhomocysteinaemia, compared to the group of patients with the concentration of homocysteine oscillating within the reference values (Table  3) . After administration of the folic acid, the average concentration of triglycerides rose slightly, although this change was not statistically significant (Table 2) . However, considerable differences were observed in the levels of apoAI and apoB, before and after the supplementation with folic acid. The apoAI concentration increased in 23 (85%) patients suffering from primary hypertension and normohomocysteinaemia and in 14 (93%) patients with hyperhomocysteinaemia (Table 3) . On the other hand, the concentration of apoB decreased in 25 (96%) patients suffering from primary hypertension and normohomocysteinaemia and in 13 (93%) patients with hyperhomocysteinaemia (Table 3) . A statistically significant correlation was recorded between the reduction of homocysteine concentration and the growth of HDL-cholesterol concentration, as well as between the change in folic acid concentration and the growth of apoAI following the folic acid supplementation. No significant relationship was noted when analysing the correlation between the decrease in homocysteine and the decrease in total cholesterol, LDL-cholesterol and apoB or the increase in triglycerides. Likewise, no significant correlations were observed between the growth in folic acid concentration in the serum of patients with primary hypertension and changes in total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides or apoB after the supplementation with folic acid (Table 4) .
DISCUSSION
In numerous studies it has been shown that hyperhomocysteinaemia causes higher risk of the development of heart diseases and cerebral stroke (3, 4) . Hyperhomocysteinaemia is one of the factors which could, in a simple and inexpensive manner, be modified through diet modification, giving up smoking, increase of physical activity and administration of folic acid, vitamin B12 and vitamin B6. Contemporary studies have shown that the biggest impact on the reduction of the concentration of homocysteine can be attributed to folic acid (4, 5) . The elimination of the folic acid deficiency triggers increased methyl-group availability, which exerts a positive impact on the homocysteine remethylation and, as a result, reduces its concentration in cells and serum (6). According to the paper by a research group, Homocysteine Lowering Trialists' Collaboration published in 2005, the results of folic acid supplementation depend on the dose and initial homocysteine and folic acid concentrations in serum of patients subject to the therapy. The highest reduction of the homocysteine concentration was found in patients with simultaneous highest homocysteine concentrations and lowest folic acid concentrations (4, 7) . In the research presented in this paper, the patients suffering from primary hypertension were given 15 mg of folic acid daily for 45 d. As a consequence, the average homocysteine concentration decreased significantly. This effect was visible especially in patients with primary hypertension and hyperhomocysteinaemia-in this group the homocysteine concentration fell by 35.0%. As a result, the number of patients suffering from primary hypertension and hyperhomocysteinaemia dropped from 35.7% to 7.1%. Similarly, the reduction of homocysteine concentration after the administration of folic acid was also observed by Mierzecki et al., Sultan et al., and others (8) (9) (10) (11) . The administration of folic acid seems to be beneficial as a consequence of the reduction of homocysteine concentration. The effects of hyperhomocysteinaemia, such as elevated oxidative stress, reduction of nitric oxide bioavailability, endothelial dysfunction or increasing thrombosis, should also be alleviated. In order to prove this hypothesis, a number of research projects were launched, analysing the impact of therapy aimed at the decrease of the homocysteine concentration on the development of atheromatous diseases, and its impact on other risk factors of the diseases. It needs to be highlighted that hyperhomocysteinaemia is rarely the only factor leading to the development of cardiovascular diseases. It is often accompanied by obesity, carbohydrate metabolism disorders and low grade inflammation of vascular walls, as well as disturbances in lipid and lipoprotein metabolism. According to the literature, hyperhomocysteinaemia may intensify disturbances in lipid and lipoprotein metabolism by oxidative modification and LDL thiolation, as well as inhibited paraoxonase activity and disturbed apoAI synthesis (12) (13) (14) . The correlation between the lipid metabolism and homocysteine concentration in patients with atherosclerosis has been studied, inter alia, by Olszewski and McCully. The results of the study showed that patients with increased homocysteine concentrations had also higher LDL-cholesterol concentrations, as compared to patients whose concentration levels remain within the desired limits (15) . On the other hand, Knekt et al. stated that increased homocysteine concentration in serum is directly proportional to the occurrence of hypertension and the level of triglycerides in serum (16) . Liao et al. observed the reduction of HDL-cholesterol and apoprotein AI in patients with homocysteine concentrations higher than reference values (13) . Furthermore, a significant population study performed in 2009 showed a significant correlation between homocysteine and HDL-cholesterol concentrations (12) . Similar results we obtained in a previous study among patients with hypertension (1). In light of the above, it may be suggested that reducing the homocysteine concentration can have a positive impact on the parameters of lipid and lipoprotein metabolism. In the research presented in this paper, the intake of folic acid by patients suffering from primary hypertension not only lowered the homocysteine concentration, but also modified the parameters of lipid and lipoprotein metabolism. The concentration of total cholesterol and LDL-cholesterol was reduced, but it was not statistically significant. Papandreou et al. found a significant reduction in total cholesterol in children to whom 5 mg of folic acid was administered twice a week for 2 consecutive months (17) . Mierzecki et al. also observed an LDL-cholesterol decrease and apoAI concentration increase following a 3-mo supplementation with folic acid (0.4 mg per day) to patients who experienced cerebral stroke at a young age (8) . Moreover, Bukowska et al. discovered that after giving young men a drink containing 250 mg of folic acid twice a day for 4 wk, the average homocysteine concentration dropped by 31.6%, LDL cholesterol decreased considerably and, at the same time, HDL-cholesterol increased, which considerably improved the atherogenic index (LDL-Ch/HDL-Ch) (18) . The present study also showed a significant increase in HDL-cholesterol and apoprotein AI concentration after the administration of folic acid.
Higher concentration of HDL-cholesterol in serum of patients suffering from primary hypertension facilitates the reverse cholesterol transport processes from peripheral tissues to the liver, where it might be transformed into bile acids and removed from the system. An increase in HDL-cholesterol concentration may be an indirect effect of the reduction of the homocysteine concentration by folic acid. The administration of folic acid influences the efficiency of the process of remethylation of homocysteine to methionine (1) .
Hyperhomocysteinaemia distorts the synthesis of one of the basic components of HDL-apoAI; therefore, the reduction of the homocysteine concentration may result in an increased concentration of this protein (13) . It is well known that the presence of apoAI particles conditions stable HDL formation, activates acyltransferase lecithin-cholesterol (EC 2.3.1.43) and interaction with peripheral cells receptors. Moreover, the influence of a high level of homocysteine on disturbances in HDLcorpuscle maturation and higher clearance of cholesterol esters, probably in a mechanism of binding the hepatic receptor SRB-I, was observed (13, 19) . Probably decreasing the homocysteine level can improve HDL-C metabolism and increase the concentration of this lipoprotein fraction in serum. A higher concentration of HDL particles and lower concentration of homocysteine can lead to an increase in paraoxonase activity-PON-1 (EC 3.1.8.1). This enzyme comprises HDL particles and takes part in antioxidative reactions, and among others prevents oxidative modification of LDL, whereas hyperhomocysteinaemia inhibits its expression (20) . However, studies conducted by other researchers who examined the impact of the reduction of homocysteine concentration in patients with primary hypertension on the indices of metabolic disturbances, do not always show benefits of this therapy. In a randomised study carried out on patients after cardiac infarct with hypercholesterolaemia (total cholesterol .6.5 mmol/L) who were given fluvastatin, 50% of them were also given folic acid (5 mg per day). The other 50% constituted a control group. After one year of observation, it was agreed that the intake of folic acid did not improve the therapeutic effect of the statin applied. The reduction of total cholesterol concentration was similar in patients administered with fluvastatin only and in those who were also given folic acid. In both groups, severe cardiovascular complications occurred with the same frequency-in 31% of patients (21) . The results of the research concerning the impact of the reduction of homocysteine concentration through supplementation with folic acid, vitamin B12 and vitamin B6 on the risk of the occurrence of cardiovascular diseases and the development of hypertension are not unambiguous. The results of the first population cohort studies showed that a lowering of the homocysteine concentration by 3 mmol/L (through the intake of folic acid) mitigates the risk of development of cardiovascular diseases by 11-16%, and cerebral stroke by 19-24% (22) . Recent intervention studies, such as HOPE-2, NORVIT, WAFAC and VISP, however, have not discovered any benefits of the supplementation with folic acid combined with the intake of vitamin B12 and B6, with the exception of a decrease in the number of cerebral strokes (11, (23) (24) (25) . Therefore, some researchers hypothesise that homocysteine is not a risk factor of cardiovascular diseases but only a signal of disturbances related to atherosclerotic processes in the vessel wall (26, 27) . Analysis of the literature data shows that study results concerning the reduction of homocysteine concentration represent the effects regarding the alleviation of hyperhomocysteinaemia, effects of medication and vitamin intake, and the advancement of pathological processes in examined patients. The scientific community continues to discuss the need for further perspectives of studies on hyperhomocysteinaemia (26, 28, 29) . The results of these examinations, although difficult to conduct from the logistic point of view and requiring a long observation period, can give responses to many current questions concerning hyperhomocysteinaemia.
In the clinical trial, lowering of blood pressure in patients was also observed. However, it needs to be pointed out that not only the administration of folic acid could influence the lowering of blood pressure in these patients, because they continued their previously described treatment. To some extent, however, it can be the effect of the administration of folic acid. 5-Metylotetrahydropholian prevents oxidation, stabilizes and regenerates tetrahydrobiopterin BH4, which is a cofactor necessary in the reaction of the release of nitric oxide catalyzed by endothelium synthase eNOS lowering the concentration of homocysteine (30) . Moreover, the lowering of the level of homocysteine in patients after the administration of folic acid can overcome adverse effects of hyperhomocysteinaemia, such as the increase of oxide stress and lowering of the bioavailability of nitric oxide (1, 2) .
CONCLUSIONS
The reduction of homocysteine concentration through the supplementation with folic acid can cause quantitative changes in some lipid and lipoprotein parameters which, in consequence, may lead to the mitigation of risk concerning the development of atherosclerosis.
